Tazarotene

DEA Class; Rx

Common Brand Names; Avage, Tazorac, Fabior, Arazlo

• Acne Agents, Topical; 
• Antipsoriatics, Topical; 
• Retinoid-like Agents, Topical

Indicated for the treatment of  for the treatment of plaque psoriasis.

Pregnancy

Hypersensitivity

• Scaling (51%)
• Erythema (34-49%)
• Desquamation (40%)
• Burning/stinging (22-30%)
• Itching (29%)
• Dry skin (15%)
• Skin irritation (10%)
• Pruritus (10%)
• Irritant contact dermatitis (8%)
• Stinging (3%)
• Rash (3%)
• Cheilitis (1%)

Propellant in foam is flammable; avoid fire, flame, and/or smoking during and immediately following application

There are no adequate and well-controlled studies with use in pregnant women

Contraindicated in females who are or may become pregnant

Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed child from therapy or from the underlying maternal condition

1 application per day topically.

1 application per day topically.

17 years: 1 application per day topically.
less than 17 years: 1 application per day topically; safety and efficacy of Avage 0.1% cream have not been established.

12 years: 1 application per day topically; safety and efficacy of Avage 0.1% cream have not been established.
9 to 12 years: 1 application per day topically for Arazlo 0.045% lotion; safety and efficacy of other formulations have not been established
less than 9 years: Safety and efficacy have not been established.

Safety and efficacy have not been established.

Safety and efficacy have not been established.

Tazarotene

cream, topical

• 0.1% (Avage, Tazorac, generic)

gel, topical

• 0.05% (Tazorac, generic)
• 0.1% (Tazorac, generic)

foam, topical

• 0.1% (Fabior)

lotion, topical

• 0.045% (Arazlo)